Rislenemdaz
http://dbpedia.org/resource/Rislenemdaz an entity of type: Thing
Rislenemdaz (developmental code names CERC-301, MK-0657) is an orally-active, selective NMDA receptor subunit 2B (NR2B) antagonist which is under development by Cerecor in the United States as an adjunctive therapy for treatment-resistant depression (TRD). In November 2013, phase II clinical trials were initiated, and in the same month, rislenemdaz received Fast Track Designation from the Food and Drug Administration for TRD.
rdf:langString
rdf:langString
Rislenemdaz
xsd:integer
43273539
xsd:integer
1082533986
xsd:integer
19
xsd:integer
808732
xsd:integer
2068839
xsd:integer
9569140
xsd:integer
1
xsd:integer
23
xsd:integer
4
rdf:langString
D11340
xsd:integer
4
xsd:integer
2
xsd:integer
11394238
rdf:langString
CC1=CC=CCOCN2CC[C@@H]CNC3=NC=CC=N3
xsd:integer
1
rdf:langString
RECBFDWSXWAXHY-IAGOWNOFSA-N
rdf:langString
CERC-301; MK-0657
xsd:integer
5
xsd:integer
250
rdf:langString
Rislenemdaz (developmental code names CERC-301, MK-0657) is an orally-active, selective NMDA receptor subunit 2B (NR2B) antagonist which is under development by Cerecor in the United States as an adjunctive therapy for treatment-resistant depression (TRD). In November 2013, phase II clinical trials were initiated, and in the same month, rislenemdaz received Fast Track Designation from the Food and Drug Administration for TRD. A pilot study was published in 2012, and a phase II trial was completed in 2014, but was deemed insufficient. A second attempt at a phase II trial in 2016 also found that the drug failed to demonstrate efficacy against depression.
xsd:nonNegativeInteger
13245
xsd:string
808732-98-1
xsd:string
2068839
xsd:string
5HAM167S5T
xsd:string
D11340
xsd:string
11394238